Nirvana Life Sciences Ratios and Metrics

Market cap in millions CAD. Fiscal year is May - April.

Millions CAD. Fiscal year is May - Apr.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr '26 Apr 22, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022	Apr '21 Apr 30, 2021
Market Capitalization	0	1	2	1	4	-
Market Cap Growth	-97.19%	-79.00%	136.21%	-74.83%	-	-
Enterprise Value	0	1	2	1	4	-
Last Close Price	0.01	0.10	0.50	0.30	5.70	-
PB Ratio	-0.32	-0.34	-2.12	-1.09	-25.10	-
Debt / Equity Ratio	-0.20	-0.07	-0.02	-0.06	-	-
Net Debt / Equity Ratio	-0.20	-0.06	-0.02	-0.05	0.22	-0.53
Net Debt / EBITDA Ratio	-	-0.30	-0.04	-0.04	0.03	0.93
Net Debt / FCF Ratio	-0.16	-1.38	-0.14	-0.14	0.07	0.52
Quick Ratio	0.03	0.01	0.02	0.03	0.08	34.85
Current Ratio	0.03	0.01	0.02	0.07	0.22	42.41
Return on Equity (ROE)	-	-	-	-	-1105.54%	-
Return on Assets (ROA)	-1018.39%	-1059.31%	-1001.10%	-264.67%	-86.15%	-
Return on Capital Employed (ROCE)	53.30%	22.80%	62.80%	125.10%	720.60%	-59.20%
Earnings Yield	-156.45%	-72.25%	-36.15%	-145.67%	-139.42%	-
FCF Yield	-	-13.72%	-7.87%	-32.64%	-12.09%	-
Buyback Yield / Dilution	38.42%	-3.26%	-37.61%	7.05%	-5.19%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.